

BOSTON SCIENTIFIC CORP  
Form 8-K  
June 24, 2005

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): June 21, 2005

**BOSTON SCIENTIFIC CORPORATION**  
(Exact name of registrant as specified in charter)

**DELAWARE**  
(State or other  
jurisdiction of  
incorporation)

**1-11083**  
(Commission  
file number)

**04-2695240**  
(IRS employer  
identification no.)

**One Boston Scientific Place, Natick, Massachusetts**  
(Address of principal executive offices)

**01760-1537**  
(Zip code)

Registrant's telephone number, including area code: **(508) 650-8000**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 8.01. Other Events.**

On June 21, 2005, a jury in Delaware found that Boston Scientific's TAXUS<sup>®</sup> Express<sup>™</sup>, Express<sup>™</sup>, Express<sup>™</sup> Biliary, and Liberté<sup>™</sup> stents infringe a Johnson & Johnson patent, and that the Liberté stent infringes a second J&J patent. This suit was originally filed by J&J (through its subsidiary Cordis Corporation) on January 13, 2003 in the U.S. District Court for the District of Delaware. The jury only determined liability; monetary damages will be determined in a later trial. Boston Scientific intends to appeal the decision. A copy of the press release issued by the Company is attached as Exhibit 99.1 to this Report.

**Item 9.01. Financial Statements and Exhibits.**

99.1 Press Release dated June 21, 2005

---

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: June 24, 2005

By: /s/ Lawrence J. Knopf

---

Lawrence J. Knopf  
Vice President and Assistant General Counsel

**INDEX TO EXHIBITS**

Exhibit Number	Description
99.1	Press Release dated June 21, 2005

---

